Navigation Links
LA BioMed investigator Dr. Christina Wang spearheads study on new male contraceptive gel
Date:6/28/2012

Christina Wang, M.D., lead investigator at Los Angeles Biomedical Research Institute (LA BioMed) one of the leading biomedical research institutes in the country recently completed a study utilizing a new contraceptive gel that has the potential to be developed as a user controlled chemical birth control agent for males. The gel, which contains testosterone and a synthetic progestin called Nestorone, sharply lowers sperm counts in men with few side effects. The study conducted at LA BioMed and the University of Washington is funded by the National Institutes of Child Health and Human Development (NICHD).

Dr. Wang and her team, along with the team at the University of Washington, enrolled 99 men in a preliminary study of the drug combination. One third of them received a gel containing testosterone and a placebo, which was applied for six months. The remaining two thirds received a gel containing testosterone and one of the two concentrations of Nestorone. Fifty-six men completed at least 20 weeks of the study and adhered to the protocol.

The results of the study were reported at the recent Endocrine Society Meeting & Expo in Houston. Of the men receiving the drug combination, 88 to 89 percent achieved a sperm concentration of less than 1 million sperm per milliliter, while those receiving testosterone and the placebo achieved the same low sperm concentration in 23 percent of men. Depending on the dosage, there was a complete absence of sperm in 78 and 69 percent of the men receiving the drug combination, and in 23 percent of the men receiving testosterone and the placebo.

"Up until now, the responsibility for contraception has traditionally always been with the female," said Dr. Wang. "With these new contraceptive methods for males, the responsibility will be shared. While this gel has great potential and minimal side effects, it does warrant further study as a male contraceptive."

Dr. Wang is a renowned andrologist/endocrinologist and a world leader in efforts to develop a safe, effective and reversible hormonal male contraceptive. In addition to this study, she is also working on a Phase I single dose and multiple dose study that tests the safety and tolerability of a new androgen dimethandrolone undecanoate that is being developed as a potential male contraceptive agent by the National Institute of Child Health and Human Development.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
2. UMMS researcher Victor Ambros, Ph.D., named co-recipient of 2012 Janssen Award for Biomedical Research
3. UCSC physicist Alexander Sher named Pew Scholar in the Biomedical Sciences
4. Applied nanobiomedicine: Exploiting nanoparticles to hunt for hidden cancer cells
5. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
6. LA BioMed receives Grand Challenges Explorations grant
7. Biomedical researchers receive Hartwell Foundation awards
8. LA BioMeds Dr. John Tsuang examines effects of Ibudilast and metamphetamines
9. Leading health care quality expert is 2012 AcademyHealth Distinguished Investigator
10. Damon Runyon Cancer Research Foundation awards $3.3 million to 8 top young clinical investigators
11. Pediatric kidney expert receives Young Investigator Award from American Transplant Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2019)... ... November 15, 2019 , ... ... United States, access to cannabis via well-managed dispensaries becomes more and more important, ... Plans, industry-leading online provider of state-of-the-art, online, custom cannabis business plans is now ...
(Date:11/15/2019)... ... November 15, 2019 , ... Spectrum ... Newsday’s Top Long Island Workplaces for 2019. The recently announced rankings honor those ... process, Newsday worked in partnership with Energage to conduct surveys into organizational health ...
(Date:11/14/2019)... ... 2019 , ... EMulate Therapeutics, Inc., a clinical-stage therapeutic device ... have 5 poster presentations related to its medical devices for treating adult and ... in Phoenix, beginning on November 20 . , Two posters will ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... individuals/organizations who have truly impacted those diagnosed with infertility. This year, Academy of ... Award for Achievement, presented at the Night of Hope Gala in New York ...
(Date:11/12/2019)... ... 2019 , ... Raintree Rehab, a division of Raintree Systems ... operators throughout the United States and Physitrack, an Apple Mobility Partner and world ... joint venture to develop and market clinical outcomes data solutions. , Both companies ...
Breaking Medicine News(10 mins):
(Date:11/19/2019)... ... 18, 2019 , ... “Impact of the Biofield Energy Healing ... has been named No. 1 International Best Seller and Hot New Release on ... and Theory, and Mind-Body Connection in the USA, Canada, United Kingdom, and Australia. ...
(Date:11/19/2019)... ... November 19, 2019 , ... HashCash Consultants is going to ... part of a genome research initiative for precision drugs. , The collaboration is expected ... that patients and contributors have more control over their genome records and the way ...
(Date:11/16/2019)... , ... November 16, 2019 , ... International Splash Awards ... Tools and Apps category. , Srijan got nominated for its efforts at the ... commendable work for Estee Lauder under tools and apps category. The event was organized ...
Breaking Medicine Technology: